Retrospective observational study in patients with renal cell carcinoma treated by everolimus, mTOR inhibitor
Not Applicable
- Conditions
- Advanced renal cell carcinoma
- Registration Number
- JPRN-UMIN000004730
- Lead Sponsor
- Department of Urology, Kinki University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method 1) ORR 2) PFS
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie everolimus's efficacy in mTOR inhibition for advanced renal cell carcinoma?
How does everolimus (Afinitor) compare to tyrosine kinase inhibitors like sunitinib (Sutent) in treating advanced renal cell carcinoma patients?
Which biomarkers predict response to everolimus in JPRN-UMIN000004730's VHL-mutant clear cell renal cell carcinoma cohort?
What adverse events are associated with everolimus in advanced renal cell carcinoma and how are they managed?
What combination therapies with everolimus show improved outcomes in advanced renal cell carcinoma compared to monotherapy?